Ciprofibrate and Pre-diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

November 1, 2018

Primary Completion Date

November 6, 2020

Study Completion Date

November 13, 2020

Conditions
Myocardial Insulin SensitivityImpaired Glucose MetabolismDiastolic Dysfunction
Interventions
DRUG

Ciprofibrate 100Mg Tablet

Ciprofibrate is a PPARα ligand and is considered to be a major regulator of the lipid metabolism. PPARα regulates the genes involved in mitochondrial function and fat metabolism and is therefore abundantly expressed in tissues that require high rates of FFA oxidation, like for instance in the heart and activation of PPARα in the heart may have beneficial effects on mitochondrial function and fat oxidative capacity.

DRUG

Placebo Oral Tablet

To compare ciprofibrate

Trial Locations (1)

6200MD

Nutrition and Movement Sciences, Maastricht

All Listed Sponsors
collaborator

Maastricht University

OTHER

lead

Maastricht University Medical Center

OTHER

NCT03662984 - Ciprofibrate and Pre-diabetes | Biotech Hunter | Biotech Hunter